Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
West Nile virus (WNV) RNA is the single-stranded, positive-sense genomic material of the West Nile virus, a mosquito-borne flavivirus (Brinton, 2002). The genome is approximately 11 kilobases long and encodes a single polyprotein that is post-translationally cleaved into three structural and seven non-structural proteins (Colpitts et al., 2012). The RNA itself is a critical therapeutic target because it serves as the primary template for both protein translation and viral replication within the host cell cytoplasm. Highly conserved secondary structures within the 5' and 3' untranslated regions (UTRs) are essential for viral RNA synthesis and packaging, making them attractive sites for therapeutic intervention (Functions of the Flavivirus 3' Untranslated Region, 2014). Experimental strategies targeting WNV RNA include antisense oligonucleotides (ASOs), phosphorodiamidate morpholino oligomers (PMOs), and small interfering RNAs (siRNAs) designed to trigger RNA degradation or block translation (Deas et al., 2007). While several nucleoside analogs like Galidesivir have shown activity by inhibiting the synthesis of this RNA, no specific antiviral therapy is currently approved for human use (Julander et al., 2014). Targeting the RNA directly aims to halt viral production and reduce the viral load in infected patients, particularly to prevent progression to severe neurological disease.
Therapeutic strategies targeting West Nile virus RNA primarily involve antisense mechanisms, where synthetic oligonucleotides bind to complementary sequences on the viral genome to sterically block translation or induce RNase H-mediated degradation (Deas et al., 2005). Additionally, RNA interference (RNAi) utilizes siRNAs to trigger the RISC complex to cleave the viral RNA (Bai et al., 2005). Nucleoside analogs also target the production of this RNA by acting as chain terminators during the replication process catalyzed by the viral RNA-dependent RNA polymerase (Julander et al., 2014).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on West Nile virus genomic RNA (WNV RNA) (WNV RNA).